Trinity Biotech plc received a non-compliance notification from Nasdaq on February 11, 2026, after its American Depositary Shares (ADSs) failed to maintain the exchange's $1.00 minimum bid price requirement. The Dublin-based diagnostics company has been granted a 180-calendar-day grace period, extending until August 10, 2026, to restore compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days.
Under Nasdaq's listing standards, the company's ADSs remain eligible for trading on the Nasdaq Global Select Market during the compliance period. Trinity Biotech's management team is currently evaluating strategic options to address the pricing deficiency and meet the exchange's requirements within the specified timeframe.
Failure to regain compliance by the deadline could result in Nasdaq initiating delisting procedures. The company's ability to restore share price stability will be closely monitored by investors and stakeholders over the coming months.